Clinical Trial

68Ga-NI-FAPI PET/CT: First-in-human Study

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 14, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
68Ga-NI-FAPI is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole (NI)-moiety and a FAP-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-NI-FAPI PET/CT in patients with different types of cancer.
Trial Details
NCT Number NCT06688305
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Malignant Neoplasm
Enrollment 40 participants
Start Date 2024-08-01
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-14